GFWA
NBIX icon

Grey Fox Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Grey Fox Wealth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16
Closed -$2.25K – 439
2025
Q3 		$2.25K Buy
+16
New +$2.17K ﹤0.01% 537

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Grey Fox Wealth Advisors's NBIX Position: Q4 2025 in Review

Grey Fox Wealth Advisors sold out of Neurocrine Biosciences (NBIX) in Q4 2025, closing a stake of 16 shares — an estimated $2.25K sold.

Grey Fox Wealth Advisors first reported a position in NBIX in Q3 2025 and held it in 1 quarter. The position peaked at $2.25K in Q3 2025. 731 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

  • Grey Fox Wealth Advisors reported no remaining Neurocrine Biosciences position as of Q4 2025 after selling out during the quarter.
  • Grey Fox Wealth Advisors sold 16 Neurocrine Biosciences shares in Q4 2025, an estimated $2.25K.
  • Grey Fox Wealth Advisors first reported a position in Neurocrine Biosciences in Q3 2025 and held it in 1 quarter.
  • Grey Fox Wealth Advisors's Neurocrine Biosciences position peaked at $2.25K in Q3 2025.
  • 731 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on Grey Fox Wealth Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.